JNJ 108.67 Johnson & Johnson $JNJ Hit a 52 week hi
Post# of 129
Posted On: 11/12/2014 12:44:18 PM
JNJ 108.67 Johnson & Johnson $JNJ Hit a 52 week high of 108.75 Closing the day 09:45 at 108.67 -0.24 -0.22% With a day low of 108.39 and a total volume of 422,958.
JNJ Recent Posts: http://investorshangout.com/Johnson--Johnson-JNJ-51518/
JNJ Johnson & Johnson Recent Headline News
Don't Dump Your Johnson & Johnson Shares For VHT Just Quite Yet
Investing Doc - Seeking Alpha - 38 mins ago
In a recent article , fellow contributor Larry Meyers contends that investors in Johnson & Johnson (NYSE: JNJ ) should exit their shares and instead redeploy their capital in the Vanguard Health Care ETF (NYSEARCA: VHT ). His investment is based...
JNJ: 108.80 (-0.11), VHT: 124.53 (-0.06)
Early Glance: Pharmaceuticals companies
AP - 1 hr 38 mins ago
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 108.80 (-0.11), BAX: 71.03 (+0.27), PFE: 30.49 (+0.17), BMY: 58.78 (+0.06)
Early Glance: Medical Devices companies
AP - 1 hr 38 mins ago
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
ZMH: 110.81 (-0.26), JNJ: 108.80 (-0.11), MDT: 68.68 (-0.31), BAX: 71.03 (+0.27)
The Secret Ingredient Of Dividend Growth Stocks
Dividends4Life - at Seeking Alpha - Wed Nov 12, 8:31AM CST
When people learn that I am an income investor it is not uncommon for them to ask why I invest in stocks instead of other "safer" alternatives such as bonds, high yield money market accounts [MMA] or certificates of deposits [CD]. I...
KO: 42.74 (+0.23), JNJ: 108.80 (-0.11), GD: 141.51 (+0.21), MCD: 95.19 (+0.05), PG: 89.72 (+0.05)
Should Johnson & Johnson Buy Medivation Inc.?
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 12, 6:55AM CST
Source: Johnson & Johnson. Johnson & Johnson is losing the battle for prostate cancer market share to the far smaller Medivation , but that may not mean that J&J should step up and acquire the company. First, a little...
MDVN: 107.03 (-0.26), JNJ: 108.80 (-0.11)
Amcor Rigid Plastics Renews National Sponsorship of America Recycles Day 2014
Business Wire - Tue Nov 11, 6:29PM CST
Amcor Rigid Plastics, one of the world's leading manufacturers of rigid plastic packaging, has announced its second year of sponsorship of America Recycles Day 2014, a national initiative of Keep America Beautiful, a U.S.-based non-profit organization that focuses on consumer environmental education and awareness.
JNJ: 108.80 (-0.11), NOC: 136.65 (-0.20)
Final Glance: Medical Devices companies
AP - Tue Nov 11, 5:02PM CST
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
ZMH: 110.81 (-0.26), JNJ: 108.80 (-0.11), MDT: 68.68 (-0.31), BAX: 71.03 (+0.27)
Final Glance: Pharmaceuticals companies
AP - Tue Nov 11, 5:02PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 108.80 (-0.11), BAX: 71.03 (+0.27), PFE: 30.49 (+0.17), BMY: 58.78 (+0.06)
Achillion Jumps on Encouraging Data on its HCV Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 4:10PM CST
Shares of Achillion Pharmaceuticals (ACHN) soared over 27% after the company reported encouraging interim results on ACH-3102.
JNJ: 108.80 (-0.11), GILD: 106.88 (-1.13), ACHN: 13.35 (+0.87), AMAG: 35.12 (+0.24)
Amgen's brodalumab beats Stelara in Phase 3 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:52PM CST
CANF: 2.52 (-0.13), JNJ: 108.80 (-0.11), IDRA: 2.47 (-0.11), DERM: 16.01 (-0.02), MRK: 59.37 (unch), PFE: 30.49 (+0.17), AZN: 74.29 (+0.09), AMGN: 162.66 (+0.24), GSK: 45.61 (-0.35), HSP: 58.15 (+0.84), NVS: 92.88 (+0.11), CELG: 107.60 (-0.25)
Dendreon Shares Plummet After It Files for Bankruptcy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 3:45PM CST
Dendreon filed voluntary petitions under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware.
MDVN: 107.03 (-0.26), AGN: 196.63 (+1.29), JNJ: 108.80 (-0.11), DNDN: 0.17 (+0.02)
DexCom Scales 52-Week High on Product Pipeline Strength - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 1:10PM CST
Impressive third-quarter 2014 results, recent FDA approvals for its new products along with a robust product pipeline contribute to the growth trajectory of DexCom, Inc. (DXCM), creating good momentum for 2015 as well.
ABT: 44.28 (+0.03), JNJ: 108.80 (-0.11), DXCM: 53.32 (+0.18), MDT: 68.68 (-0.31)
Midday Glance: Pharmaceuticals companies
AP - Tue Nov 11, 12:52PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 108.80 (-0.11), BAX: 71.03 (+0.27), PFE: 30.49 (+0.17), BMY: 58.78 (+0.06)
Midday Glance: Medical Devices companies
AP - Tue Nov 11, 12:52PM CST
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
ZMH: 110.81 (-0.26), JNJ: 108.80 (-0.11), MDT: 68.69 (-0.30), BAX: 71.03 (+0.27)
Reinvesting Dividends Turbo-Charges Total Returns And Helps Protect Against Market Panic
David Van Knapp - at Seeking Alpha - Tue Nov 11, 12:40PM CST
KO: 42.74 (+0.23), JNJ: 108.80 (-0.11), SPY: 204.09 (-0.09), PG: 89.72 (+0.05), O: 46.50 (-0.33), CVX: 118.21 (-0.23), BRK.B: 145.56 (+0.61), BRK.A: 218,400.00 (+1,047.30)
Gilead presents Harvoni data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 10:03AM CST
JNJ: 108.80 (-0.11), GILD: 106.90 (-1.11), ACHN: 13.35 (+0.87), CNAT: 7.06 (unch), MRK: 59.37 (unch), RGLS: 20.00 (-0.47), ABBV: 63.93 (+0.08), BMY: 58.78 (+0.06), ENTA: 43.30 (+0.08)
AbbVie presents HCV/HIV and liver transplant HCV data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 9:07AM CST
JNJ: 108.80 (-0.11), GILD: 106.90 (-1.11), ACHN: 13.35 (+0.87), CNAT: 7.06 (unch), MRK: 59.37 (unch), RGLS: 20.00 (-0.47), ABBV: 63.94 (+0.09), BMY: 58.78 (+0.06), ENTA: 43.30 (+0.08)
Global Hospital Pharmaceuticals Market Outlook 2020: AstraZeneca, Bayer, Eli Lilly and Co, GSK, J&J, Merck Pfizer & Sanofi-Aventis Dominate the $10 Billion Market
M2 - Tue Nov 11, 9:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/g45smv/hospital) has announced the addition of the "Hospital Pharmaceuticals Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. The global hospital pharmaceuticals market was valued at USD 2.65 billion in 2013 and is estimated to reach USD 10.90 billion in 2020, declining with a CAGR of (11.5)% from 2014 to 2020 The oncology segment accounts for the largest market share in 2013 wherein the immunomodulating agent holds the maximum share among other drug class commonly prescribed in hospital settings. Followed by oncology, cardiovascular disease account for the second largest share in which anti-cholinergic agent has the fastest declining growth rate. Decline in anti-cholinergic agent is primarily due to exclusivity loss of several high selling drugs such as VESIcare and Enablex which will lose their patent rights in 2015 and 2018 respectively. Geographically, North America region constitutes the largest market for global hospital pharmaceuticals market in 2013; however, Asia-Pacific is predicted to foresee the highest growth rate during the forecast period from 2014 to 2020. This growth has been attributed to large population base and increasing incidences of cardiovascular diseases and cancer incidences in both of the emerging regions. Moreover, according to the Central Bureau of Health Intelligence, the number of government hospitals in India increased from 4,571 in 2000 to 11,993 in 2011. Rising number of hospitals and growing awareness about branded drugs for treating chronic disease conditions is fueling the demand for hospital pharmaceuticals in these regions. Additionally, significant growth in medical tourism in Asia Pacific, Africa, the Middle East and Latin America would boost the hospital pharmaceuticals market. The leading market players in this market include AstraZeneca plc, Bayer AG, Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc., Sanofi -Aventis. Scope of the Report Cardiology - Anti-Adrenergic Drugs - Calcium Channel Blockers - Diuretic Drugs - Anti-Arrhythmic Drugs - Others Oncology - Alkylating Agents - Anti-Metabolites - Hormonal Agents - Immunomodulating Agents - Miscellaneous Drugs Nephrology and Urology - Diuretic Agents - Anti-Hypertensive Agents - Phosphate Binders - Anticholinergic Drugs - 5-Alpha Reductase Inhibitors Neurology - Anti-Anxiety Agents - Detail2Anti-Migraine Drugs - Antidepressant Drugs - Anti-Psychotic Drugs Pain - Anticonvulsant Drugs - Anesthetic Drugs - Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) - Opioids - Non-Narcotics Analgesic Drugs Infection - Antibacterial Drugs - Antiviral Drugs - Antifungal Drugs - Antiparasite Drugs Global Hospital Pharmaceuticals Market, by Major Indications Cardiology - Coronary Heart Diseases - Stroke - High Blood Pressure - Heart Failure - Others Oncology - Lung Cancer - Breast Cancer - Colorectal Cancer - Prostate Cancer - Others Nephrology and Urology - Acute Kidney Failure - Chronic Kidney Diseases - Glomerular Diseases - Diabetes - Others Neurology - Epilepsy - Alzheimer;s Disease - Parkinson;s Disease - Multiple Sclerosis - Others Pain - Neuropathic Pain - Fibromyalgia - Osteoarthritis - Rheumatoid Arthritis - Cancer Pain Infection - Detail1Tuberculosis - Pneumonia - Hepatitis A - Hepatitis B - Candida Infection - Fungal Meningitis - Shigellosis - Amoebiasis - Other For more information visit http://www.researchandmarkets.com/research/g45smv/hospital
JNJ: 108.80 (-0.11), PFE: 30.49 (+0.17), MRK: 59.37 (unch), AZN: 74.29 (+0.09), LLY: 67.80 (-0.05), GSK: 45.61 (-0.35)
JNJ Recent Posts: http://investorshangout.com/Johnson--Johnson-JNJ-51518/
JNJ Johnson & Johnson Recent Headline News
Don't Dump Your Johnson & Johnson Shares For VHT Just Quite Yet
Investing Doc - Seeking Alpha - 38 mins ago
In a recent article , fellow contributor Larry Meyers contends that investors in Johnson & Johnson (NYSE: JNJ ) should exit their shares and instead redeploy their capital in the Vanguard Health Care ETF (NYSEARCA: VHT ). His investment is based...
JNJ: 108.80 (-0.11), VHT: 124.53 (-0.06)
Early Glance: Pharmaceuticals companies
AP - 1 hr 38 mins ago
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 108.80 (-0.11), BAX: 71.03 (+0.27), PFE: 30.49 (+0.17), BMY: 58.78 (+0.06)
Early Glance: Medical Devices companies
AP - 1 hr 38 mins ago
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
ZMH: 110.81 (-0.26), JNJ: 108.80 (-0.11), MDT: 68.68 (-0.31), BAX: 71.03 (+0.27)
The Secret Ingredient Of Dividend Growth Stocks
Dividends4Life - at Seeking Alpha - Wed Nov 12, 8:31AM CST
When people learn that I am an income investor it is not uncommon for them to ask why I invest in stocks instead of other "safer" alternatives such as bonds, high yield money market accounts [MMA] or certificates of deposits [CD]. I...
KO: 42.74 (+0.23), JNJ: 108.80 (-0.11), GD: 141.51 (+0.21), MCD: 95.19 (+0.05), PG: 89.72 (+0.05)
Should Johnson & Johnson Buy Medivation Inc.?
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 12, 6:55AM CST
Source: Johnson & Johnson. Johnson & Johnson is losing the battle for prostate cancer market share to the far smaller Medivation , but that may not mean that J&J should step up and acquire the company. First, a little...
MDVN: 107.03 (-0.26), JNJ: 108.80 (-0.11)
Amcor Rigid Plastics Renews National Sponsorship of America Recycles Day 2014
Business Wire - Tue Nov 11, 6:29PM CST
Amcor Rigid Plastics, one of the world's leading manufacturers of rigid plastic packaging, has announced its second year of sponsorship of America Recycles Day 2014, a national initiative of Keep America Beautiful, a U.S.-based non-profit organization that focuses on consumer environmental education and awareness.
JNJ: 108.80 (-0.11), NOC: 136.65 (-0.20)
Final Glance: Medical Devices companies
AP - Tue Nov 11, 5:02PM CST
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
ZMH: 110.81 (-0.26), JNJ: 108.80 (-0.11), MDT: 68.68 (-0.31), BAX: 71.03 (+0.27)
Final Glance: Pharmaceuticals companies
AP - Tue Nov 11, 5:02PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 108.80 (-0.11), BAX: 71.03 (+0.27), PFE: 30.49 (+0.17), BMY: 58.78 (+0.06)
Achillion Jumps on Encouraging Data on its HCV Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 4:10PM CST
Shares of Achillion Pharmaceuticals (ACHN) soared over 27% after the company reported encouraging interim results on ACH-3102.
JNJ: 108.80 (-0.11), GILD: 106.88 (-1.13), ACHN: 13.35 (+0.87), AMAG: 35.12 (+0.24)
Amgen's brodalumab beats Stelara in Phase 3 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:52PM CST
CANF: 2.52 (-0.13), JNJ: 108.80 (-0.11), IDRA: 2.47 (-0.11), DERM: 16.01 (-0.02), MRK: 59.37 (unch), PFE: 30.49 (+0.17), AZN: 74.29 (+0.09), AMGN: 162.66 (+0.24), GSK: 45.61 (-0.35), HSP: 58.15 (+0.84), NVS: 92.88 (+0.11), CELG: 107.60 (-0.25)
Dendreon Shares Plummet After It Files for Bankruptcy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 3:45PM CST
Dendreon filed voluntary petitions under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware.
MDVN: 107.03 (-0.26), AGN: 196.63 (+1.29), JNJ: 108.80 (-0.11), DNDN: 0.17 (+0.02)
DexCom Scales 52-Week High on Product Pipeline Strength - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 1:10PM CST
Impressive third-quarter 2014 results, recent FDA approvals for its new products along with a robust product pipeline contribute to the growth trajectory of DexCom, Inc. (DXCM), creating good momentum for 2015 as well.
ABT: 44.28 (+0.03), JNJ: 108.80 (-0.11), DXCM: 53.32 (+0.18), MDT: 68.68 (-0.31)
Midday Glance: Pharmaceuticals companies
AP - Tue Nov 11, 12:52PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 108.80 (-0.11), BAX: 71.03 (+0.27), PFE: 30.49 (+0.17), BMY: 58.78 (+0.06)
Midday Glance: Medical Devices companies
AP - Tue Nov 11, 12:52PM CST
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
ZMH: 110.81 (-0.26), JNJ: 108.80 (-0.11), MDT: 68.69 (-0.30), BAX: 71.03 (+0.27)
Reinvesting Dividends Turbo-Charges Total Returns And Helps Protect Against Market Panic
David Van Knapp - at Seeking Alpha - Tue Nov 11, 12:40PM CST
KO: 42.74 (+0.23), JNJ: 108.80 (-0.11), SPY: 204.09 (-0.09), PG: 89.72 (+0.05), O: 46.50 (-0.33), CVX: 118.21 (-0.23), BRK.B: 145.56 (+0.61), BRK.A: 218,400.00 (+1,047.30)
Gilead presents Harvoni data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 10:03AM CST
JNJ: 108.80 (-0.11), GILD: 106.90 (-1.11), ACHN: 13.35 (+0.87), CNAT: 7.06 (unch), MRK: 59.37 (unch), RGLS: 20.00 (-0.47), ABBV: 63.93 (+0.08), BMY: 58.78 (+0.06), ENTA: 43.30 (+0.08)
AbbVie presents HCV/HIV and liver transplant HCV data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 9:07AM CST
JNJ: 108.80 (-0.11), GILD: 106.90 (-1.11), ACHN: 13.35 (+0.87), CNAT: 7.06 (unch), MRK: 59.37 (unch), RGLS: 20.00 (-0.47), ABBV: 63.94 (+0.09), BMY: 58.78 (+0.06), ENTA: 43.30 (+0.08)
Global Hospital Pharmaceuticals Market Outlook 2020: AstraZeneca, Bayer, Eli Lilly and Co, GSK, J&J, Merck Pfizer & Sanofi-Aventis Dominate the $10 Billion Market
M2 - Tue Nov 11, 9:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/g45smv/hospital) has announced the addition of the "Hospital Pharmaceuticals Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. The global hospital pharmaceuticals market was valued at USD 2.65 billion in 2013 and is estimated to reach USD 10.90 billion in 2020, declining with a CAGR of (11.5)% from 2014 to 2020 The oncology segment accounts for the largest market share in 2013 wherein the immunomodulating agent holds the maximum share among other drug class commonly prescribed in hospital settings. Followed by oncology, cardiovascular disease account for the second largest share in which anti-cholinergic agent has the fastest declining growth rate. Decline in anti-cholinergic agent is primarily due to exclusivity loss of several high selling drugs such as VESIcare and Enablex which will lose their patent rights in 2015 and 2018 respectively. Geographically, North America region constitutes the largest market for global hospital pharmaceuticals market in 2013; however, Asia-Pacific is predicted to foresee the highest growth rate during the forecast period from 2014 to 2020. This growth has been attributed to large population base and increasing incidences of cardiovascular diseases and cancer incidences in both of the emerging regions. Moreover, according to the Central Bureau of Health Intelligence, the number of government hospitals in India increased from 4,571 in 2000 to 11,993 in 2011. Rising number of hospitals and growing awareness about branded drugs for treating chronic disease conditions is fueling the demand for hospital pharmaceuticals in these regions. Additionally, significant growth in medical tourism in Asia Pacific, Africa, the Middle East and Latin America would boost the hospital pharmaceuticals market. The leading market players in this market include AstraZeneca plc, Bayer AG, Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc., Sanofi -Aventis. Scope of the Report Cardiology - Anti-Adrenergic Drugs - Calcium Channel Blockers - Diuretic Drugs - Anti-Arrhythmic Drugs - Others Oncology - Alkylating Agents - Anti-Metabolites - Hormonal Agents - Immunomodulating Agents - Miscellaneous Drugs Nephrology and Urology - Diuretic Agents - Anti-Hypertensive Agents - Phosphate Binders - Anticholinergic Drugs - 5-Alpha Reductase Inhibitors Neurology - Anti-Anxiety Agents - Detail2Anti-Migraine Drugs - Antidepressant Drugs - Anti-Psychotic Drugs Pain - Anticonvulsant Drugs - Anesthetic Drugs - Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) - Opioids - Non-Narcotics Analgesic Drugs Infection - Antibacterial Drugs - Antiviral Drugs - Antifungal Drugs - Antiparasite Drugs Global Hospital Pharmaceuticals Market, by Major Indications Cardiology - Coronary Heart Diseases - Stroke - High Blood Pressure - Heart Failure - Others Oncology - Lung Cancer - Breast Cancer - Colorectal Cancer - Prostate Cancer - Others Nephrology and Urology - Acute Kidney Failure - Chronic Kidney Diseases - Glomerular Diseases - Diabetes - Others Neurology - Epilepsy - Alzheimer;s Disease - Parkinson;s Disease - Multiple Sclerosis - Others Pain - Neuropathic Pain - Fibromyalgia - Osteoarthritis - Rheumatoid Arthritis - Cancer Pain Infection - Detail1Tuberculosis - Pneumonia - Hepatitis A - Hepatitis B - Candida Infection - Fungal Meningitis - Shigellosis - Amoebiasis - Other For more information visit http://www.researchandmarkets.com/research/g45smv/hospital
JNJ: 108.80 (-0.11), PFE: 30.49 (+0.17), MRK: 59.37 (unch), AZN: 74.29 (+0.09), LLY: 67.80 (-0.05), GSK: 45.61 (-0.35)
(0)
(0)Johnson & Johnson (JNJ) Stock Research Links
Scroll down for more posts ▼